VeinWay Traversa Venous Recanalization Device’s First Compassionate Use Cases Presented

June 7, 2023—VeinWay announced that the company’s Traversa venous recanalization device was used in a compassionate use case for venous recanalization to save a patient’s arm.

The Traversa procedure was performed by interventional vascular surgeon Stefan Stalhoff, MD, with Klinikum Hochsauerland in Arnsberg-Hüsten, Germany, with supervision by VeinWay scientific advisory board member Michael Lichtenberg, MD, who is Chief of Angiology at Klinikum Hochsauerland, Clinic for Angiology/Clinic for Vascular Surgery.

“By using the Traversa, we saved hours of procedure time and were able to achieve a goal previously unreachable, with comparable ease,” commented Dr. Stalhoff in the company’s press release. “This makes two successful clinical outcomes using the Traversa thus far.”

On March 2, 2023, the company announced the first-in-human compassionate use case with Traversa when the device was used for venous recanalization to save a patient’s leg that was close to being amputated. The procedure was performed by interventional radiologists David M. Williams, MD, and Minhaj S. Khaja, MD, at University of Michigan Health in Ann Arbor, Michigan.

Details of both compassionate use cases were presented by Dr. Lichtenberg at LINC, the Leipzig Interventional Course held June 6-9 in Leipzig, Germany. A brief video animation of the device is available online, noted VeinWay.

The company stated that Traversa provides physicians with a dedicated, purpose-built tool to treat deep vein thrombosis. The device allows physician’s to safely cross a variety of complicated blockages that were previously uncrossable, as well as shorten the time to cross.

VeinWay, which is based in Or Yehuda, Israel, is a portfolio company of the MedX Xelerator, a medical device incubator backed by Boston Scientific, Sheba Medical Center, MedX Ventures Group, Consensus Business Group, and West Pharmaceuticals. The company is currently engaged in a series A financing round.